Legal & General Group
DMAC icon

Legal & General Group’s DiaMedica Therapeutics DMAC Stock Holding History

Legal & General Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7K Buy
3,799
+813
+27% +$5K ﹤0.01% 2994
2026
Q1 		$20.2K Sell
2,986
-539
-15% -$4.27K ﹤0.01% 2959
2025
Q4 		$28.1K Hold
3,525
– – ﹤0.01% 2899
2025
Q3 		$24.2K Buy
3,525
+582
+20% +$3.16K ﹤0.01% 2966
2025
Q2 		$11.5K Buy
+2,943
New +$11.5K ﹤0.01% 3233

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Legal & General Group's DMAC Position: Q2 2026 in Review

Legal & General Group increased its DiaMedica Therapeutics (DMAC) stake by 27% in Q2 2026, buying an estimated $5K and bringing the position to 3,799 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Legal & General Group first reported a position in DMAC in Q2 2025 and has held it in 5 quarters since. The position peaked at $28.1K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Legal & General Group held 3,799 shares of DiaMedica Therapeutics worth $26.7K as of Q2 2026.
  • Legal & General Group bought 813 DiaMedica Therapeutics shares in Q2 2026, an estimated $5K.
  • DiaMedica Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2994 holding.
  • Legal & General Group first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Legal & General Group's DiaMedica Therapeutics position peaked at $28.1K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.